login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
GSK PLC-SPON ADR (GSK) Stock News
USA
-
New York Stock Exchange
- NYSE:GSK -
US37733W2044
-
ADR
48.27
USD
+1.08 (+2.29%)
Last: 12/2/2025, 3:42:33 PM
48.27
USD
0 (0%)
After Hours:
12/2/2025, 3:42:33 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
GSK Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Chartmill
GSK PLC-SPON ADR (NYSE:GSK) Presents a High-Probability Technical Breakout Setup
7 hours ago - By: Zacks Investment Research
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
a day ago - By: Zacks Investment Research
- Mentions:
PM
PH
NRP
GNE
...
Top Analyst Reports for Palantir, Philip Morris & TotalEnergies
6 days ago - By: Stocktwits
- Mentions:
LABU
NVO
TEVA
ABBV
...
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared
6 days ago - By: Stocktwits
- Mentions:
NVO
TEVA
LLY
PFE
...
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets
11 days ago - By: Zacks Investment Research
Why GSK (GSK) is a Top Value Stock for the Long-Term
11 days ago - By: Stocktwits
- Mentions:
ANAB
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal
14 days ago - By: Zacks Investment Research
- Mentions:
ADMA
ALEC
ARQT
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
15 days ago - By: Zacks Investment Research
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
18 days ago - By: Zacks Investment Research
- Mentions:
GILD
ALKS
FOLD
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
18 days ago - By: The Motley Fool
The Best Healthcare Stock to Hold in Uncertain Times
19 days ago - By: Zacks Investment Research
Why GSK (GSK) is a Top Growth Stock for the Long-Term
25 days ago - By: Benzinga
Looking Into GSK PLC's Recent Short Interest
a month ago - By: Zacks Investment Research
- Mentions:
PFE
MRK
MRNA
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
a month ago - By: Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
a month ago - By: Zacks Investment Research
- Mentions:
GILD
ALKS
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
a month ago - By: Zacks Investment Research
- Mentions:
PFE
MRK
MRNA
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
a month ago - By: Zacks Investment Research
- Mentions:
GILD
ALKS
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
a month ago - By: The Motley Fool
- Mentions:
PM
PFE
MTSR
2 High-Yield Stocks With Fresh Catalysts
a month ago - By: Zacks Investment Research
- Mentions:
JNJ
VIR
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
a month ago - By: Investor's Business Daily
GSK Jumps After Hiked 2025 Guidance Widely Outperforms Expectations
a month ago - By: Benzinga
- Mentions:
CGO
ROL
ESRT
NNBR
...
Earnings Scheduled For October 29, 2025
a month ago - By: Stocktwits
- Mentions:
CBLS
DIVD
GSK Buys Global Rights To Preclinical Cancer Therapy For $357M
a month ago - By: Investor's Business Daily
- Mentions:
AAPL
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
a month ago - By: GSK plc
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
a month ago - By: Zacks Investment Research
- Mentions:
ILMN
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
a month ago - By: Zacks Investment Research
Here's Why GSK (GSK) is a Strong Value Stock
a month ago - By: Zacks Investment Research
- Mentions:
NVS
QGEN
INCY
Will Positive Regulatory Updates Further Boost INCY Stock?
2 months ago - By: Zacks Investment Research
Why GSK (GSK) is a Top Value Stock for the Long-Term
2 months ago - By: GSK plc
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
Please enable JavaScript to continue using this application.